Recent Updates
Recently added Catalysts

Metastatic Castration Resistant Prostate Cancer: 3 biotech companies with clinical-stage programmes

OncologyConcentrated betData as of 2026-09-04

Competitors3in the clinic
Median market cap$4.0Buniverse median $1.20B
Allocated capital$2.8B$20.0B competing
Phase 3 or filed21 mid, 0 early
Pure plays0this indication only
Capital rank70/299crowding rank 61

Metastatic Castration Resistant Prostate Cancer is a concentrated bet: only 3 US-listed developers are in the clinic, and the median one is worth $4.0B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

EXEL carries 73% of the $20.0B competing here, more than the other 2 companies combined.

$2.8B of allocated capital sits in Metastatic Castration Resistant Prostate Cancer, ranking it 70th of 299 indications by the money committed to it.

Companies developing drugs for Metastatic Castration Resistant Prostate Cancer 3

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
TLXTelix Pharmaceuticals177Lu-TLX591Phase 31$4.0BNo5 11 Sep 2026
ORICOric PharmaceuticalsDarolutamidePhase 32$1.3BNo2 1 Oct 2026
EXELExelixisXL092Phase 21$14.7BNo11 3 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. EXEL holds 73% of the $20.0B competing in this indication.

Why Metastatic Castration Resistant Prostate Cancer is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Metastatic Castration Resistant Prostate Cancer has 3 competitors and a median of $4.0B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Non-Squamous Non-Small Cell Lung Cancer1 company · $2.7B · median $13.7BUncontestedProstate Cancer6 companies · $2.7B · median $1.1BKnife fightBreast Cancer10 companies · $2.7B · median $288MKnife fightGlioblastoma6 companies · $3.0B · median $432MKnife fightMeningioma3 companies · $2.5B · median $14.7BConcentrated betChronic Myelogenous Leukemia2 companies · $2.4B · median $3.0BConcentrated betPancreatic Cancer9 companies · $2.4B · median $371MKnife fightMelanoma4 companies · $2.3B · median $2.6BConcentrated bet

Metastatic Castration Resistant Prostate Cancer pipeline questions

Which biotech companies are developing drugs for Metastatic Castration Resistant Prostate Cancer?

Telix Pharmaceuticals (TLX, 177Lu-TLX591, Phase 3); Oric Pharmaceuticals (ORIC, Darolutamide, Phase 3); Exelixis (EXEL, XL092, Phase 2). Those are the 3 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Castration Resistant Prostate Cancer.

How advanced is the Metastatic Castration Resistant Prostate Cancer pipeline?

Of the 3 clinical-stage programmes in Metastatic Castration Resistant Prostate Cancer, 2 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Which company leads the Metastatic Castration Resistant Prostate Cancer field?

EXEL is the largest developer in Metastatic Castration Resistant Prostate Cancer, holding 73% of the $20.0B of market capitalisation competing in the indication. The median competitor is worth $4.0B.

When is the next Metastatic Castration Resistant Prostate Cancer catalyst?

The next dated catalyst in Metastatic Castration Resistant Prostate Cancer is TLX on 11 Sep 2026. 3 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map